Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Among authors: schafhausen p. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Vermorken JB, Peyrade F, Krauss J, Mesía R, Remenar E, Gauler TC, Keilholz U, Delord JP, Schafhausen P, Erfán J, Brümmendorf TH, Iglesias L, Bethe U, Hicking C, Clement PM. Vermorken JB, et al. Among authors: schafhausen p. Ann Oncol. 2014 Mar;25(3):682-688. doi: 10.1093/annonc/mdu003. Ann Oncol. 2014. PMID: 24567516 Free PMC article. Clinical Trial.
Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Zech HB, Moeckelmann N, Boettcher A, Muenscher A, Binder M, Vettorazzi E, Bokemeyer C, Schafhausen P, Betz CS, Busch CJ. Zech HB, et al. Among authors: schafhausen p. Future Oncol. 2020 Dec;16(36):3035-3043. doi: 10.2217/fon-2020-0595. Epub 2020 Sep 9. Future Oncol. 2020. PMID: 32902312 Clinical Trial.
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study.
Klinghammer K, Fayette J, Kawecki A, Dietz A, Schafhausen P, Folprecht G, Rottey S, Debourdeau P, Lavernia J, Jacobs A, Ahrens-Fath I, Dietrich B, Baumeister H, Zurlo A, Ochsenreither S, Keilholz U. Klinghammer K, et al. Among authors: schafhausen p. ESMO Open. 2021 Oct;6(5):100242. doi: 10.1016/j.esmoop.2021.100242. Epub 2021 Sep 2. ESMO Open. 2021. PMID: 34482179 Free PMC article. Clinical Trial.
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Neoptolemos JP, et al. JAMA. 2012 Jul 11;308(2):147-56. doi: 10.1001/jama.2012.7352. JAMA. 2012. PMID: 22782416 Clinical Trial.
Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Ocheni S, Iwanski GB, Schafhausen P, Zander AR, Ayuk F, Klyuchnikov E, Zabelina T, Fiedler W, Schnittger S, Hochhaus A, Brümmendorf TH, Kröger N, Bacher U. Ocheni S, et al. Among authors: schafhausen p. Leuk Lymphoma. 2009 Apr;50(4):551-8. doi: 10.1080/10428190902755513. Leuk Lymphoma. 2009. PMID: 19373652
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
Al-Ali HK, Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafhausen P, Tavares R, Giraldo P, Foltz L, Raanani P, Gupta V, Tannir B, Ronco JP, Ghosh J, Martino B, Vannucchi AM. Al-Ali HK, et al. Among authors: schafhausen p. Haematologica. 2016 Sep;101(9):1065-73. doi: 10.3324/haematol.2016.143677. Epub 2016 May 31. Haematologica. 2016. PMID: 27247324 Free PMC article. Clinical Trial.
91 results